CN113905724A - 包含线粒体的雾化组合物及其使用方法 - Google Patents

包含线粒体的雾化组合物及其使用方法 Download PDF

Info

Publication number
CN113905724A
CN113905724A CN202080039304.2A CN202080039304A CN113905724A CN 113905724 A CN113905724 A CN 113905724A CN 202080039304 A CN202080039304 A CN 202080039304A CN 113905724 A CN113905724 A CN 113905724A
Authority
CN
China
Prior art keywords
mitochondria
composition
lung
mitochondrial
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080039304.2A
Other languages
English (en)
Chinese (zh)
Inventor
J.D.麦卡利
P.J.德尔尼多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of CN113905724A publication Critical patent/CN113905724A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
    • A61B6/5217—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data extracting a diagnostic or physiological parameter from medical diagnostic data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08—Clinical applications
    • A61B8/0883—Clinical applications for diagnosis of the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48—Diagnostic techniques
    • A61B8/481—Diagnostic techniques involving the use of contrast agents, e.g. microbubbles introduced into the bloodstream

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
CN202080039304.2A 2019-04-15 2020-04-15 包含线粒体的雾化组合物及其使用方法 Pending CN113905724A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962834020P 2019-04-15 2019-04-15
US62/834,020 2019-04-15
PCT/US2020/028219 WO2020214644A1 (en) 2019-04-15 2020-04-15 Aerosolized compositions comprising mitochondria and methods of use thereof

Publications (1)

Publication Number Publication Date
CN113905724A true CN113905724A (zh) 2022-01-07

Family

ID=72837565

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080039304.2A Pending CN113905724A (zh) 2019-04-15 2020-04-15 包含线粒体的雾化组合物及其使用方法

Country Status (6)

Country Link
US (1) US20220395531A1 (https=)
EP (2) EP3955902B1 (https=)
JP (1) JP7590341B2 (https=)
CN (1) CN113905724A (https=)
ES (1) ES2988040T3 (https=)
WO (1) WO2020214644A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4272834T1 (sl) 2016-01-15 2026-03-31 Beth Israel Deaconess Medical Center, Inc. Terapevtska uporaba mitohondrijev in kombiniranih mitohondrijskih sredstev
EP3962365A4 (en) * 2019-05-02 2023-02-01 Children's Medical Center Corporation PROPHYLACTIC AND THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIA
KR102665782B1 (ko) * 2022-03-29 2024-05-14 주식회사 파이안바이오테크놀로지 동결 및 동결건조된 미토콘드리아 및 이의 용도
CA3257638A1 (en) * 2022-06-10 2023-12-14 Cellvie Ag COMPOSITION AND CRYOCONSERVATION PROCESS OF MITOCHONDRIA
CN115634178A (zh) * 2022-10-13 2023-01-24 广州华茜药业科技有限公司 补充机体细胞能量的线粒体组合物及其制备方法
CN115624515A (zh) * 2022-10-13 2023-01-20 广州华茜药业科技有限公司 一种抗皱抗衰的线粒体组合物及其应用
WO2025184537A1 (en) * 2024-03-01 2025-09-04 The Board Of Trustees Of The Leland Stanford Junior University Bio-engineered mitochondria for targeted delivery to cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014113638A1 (en) * 2013-01-17 2014-07-24 Aer Devices, Inc. Multi-use albuterol maintenance therapy formulations and devices therefor
CN107249600A (zh) * 2014-12-31 2017-10-13 台湾粒线体应用技术股份有限公司 新颖医药组合物及其用于治疗肺损伤的用途
US20180057610A1 (en) * 2016-01-15 2018-03-01 Children's Medical Center Corporation Therapeutic Use of Mitochondria and Combined Mitochondrial Agent

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826255A (en) 1972-06-22 1974-07-30 Hudson Oxygen Therapy Sales Co Intermittent positive pressure breathing manifold
YU41046B (en) 1974-08-22 1986-10-31 Schering Ag Medicine inholating device
US4268460A (en) 1977-12-12 1981-05-19 Warner-Lambert Company Nebulizer
US4253468A (en) 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
DE3151275C2 (de) 1981-12-24 1986-07-10 SKF GmbH, 8720 Schweinfurt Befestigungsvorrichtung für Werkzeuge
US4649911A (en) 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO2000041949A1 (en) 1999-01-18 2000-07-20 Earth Chemical Co., Ltd. Aerosol injection device
KR20100117148A (ko) * 2002-04-01 2010-11-02 지티씨바이오쎄라퓨틱스,인크. 폐 질환의 치료 방법
US8616195B2 (en) * 2003-07-18 2013-12-31 Novartis Ag Nebuliser for the production of aerosolized medication
CA2560415A1 (en) 2004-03-29 2005-10-13 The Procter & Gamble Company Aerosol
US7431222B2 (en) 2005-06-03 2008-10-07 Monterrosa Christopher H Aerosol spray masking device
IL183818A0 (en) 2007-06-10 2007-10-31 Shimon Harpaz Uniformly abrasive confectionery product and process therefor
EP2654865B1 (en) * 2010-12-22 2015-02-25 Koninklijke Philips N.V. Nebulizer device
US20160113887A1 (en) * 2014-06-05 2016-04-28 The Regents Of The University Of California Halogenated ether compounds and methods of inducing anesthesia
CN112243372A (zh) * 2018-05-31 2021-01-19 克里蒂泰克公司 从受试者分离肿瘤特异性免疫细胞用于过继性细胞疗法的方法和癌症疫苗
JP2022500059A (ja) * 2018-09-17 2022-01-04 エラスムス ユニバーシティ メディカルセンター ロッテルダムErasmus University Medical Center Rotterdam アデノソーム
JP2022542495A (ja) * 2019-07-24 2022-10-03 ルカ・サイエンス株式会社 細胞からミトコンドリアを得る方法および得られたミトコンドリア

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014113638A1 (en) * 2013-01-17 2014-07-24 Aer Devices, Inc. Multi-use albuterol maintenance therapy formulations and devices therefor
CN107249600A (zh) * 2014-12-31 2017-10-13 台湾粒线体应用技术股份有限公司 新颖医药组合物及其用于治疗肺损伤的用途
US20180057610A1 (en) * 2016-01-15 2018-03-01 Children's Medical Center Corporation Therapeutic Use of Mitochondria and Combined Mitochondrial Agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
熊振芳等: "《基础护理学》", 华中科技大学出版社, pages: 296 - 301 *

Also Published As

Publication number Publication date
EP4461369A3 (en) 2025-02-12
EP4461369A2 (en) 2024-11-13
EP3955902A1 (en) 2022-02-23
US20220395531A1 (en) 2022-12-15
EP4461369C0 (en) 2026-02-25
EP3955902A4 (en) 2023-03-22
ES2988040T3 (es) 2024-11-19
JP2022529262A (ja) 2022-06-20
JP7590341B2 (ja) 2024-11-26
WO2020214644A1 (en) 2020-10-22
EP4461369B1 (en) 2026-02-25
EP3955902B1 (en) 2024-07-17
EP3955902C0 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
EP4461369B1 (en) Aerosolized compositions comprising mitochondria and methods of use thereof
Popowski et al. Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung
Iyer et al. Nano-therapeutics for the lung: state-of-the-art and future perspectives
US8586527B2 (en) Cerivastatin to treat pulmonary disorders
CN107921062B (zh) 组织修复和再生方法
Hajos et al. Inhalable liposomal formulation for vasoactive intestinal peptide
MX2011001261A (es) Composicion parenteral que comprende microesferas con un diametro entre 10 y 20 micrometros.
JP6397984B2 (ja) 乾燥粉末ペプチド医薬
Osman et al. Inhalable DNase I microparticles engineered with biologically active excipients
US20220160782A1 (en) Treating Heart Failure
Nguyen Targeted delivery of surface-modified nanoparticles: modulation of inflammation for acute lung injury
Beck-Broichsitter et al. Evaluating the controlled release properties of inhaled nanoparticles using isolated, perfused, and ventilated lung models
Mentkowski et al. Surface engineering enhances the therapeutic potential of systemically delivered extracellular vesicles following acute myocardial infarction
CN110384681A (zh) 一种用于肺纤维化的纳米制剂及其制备方法
JP2022120034A (ja) 吸入粉末剤、その評価方法及びその用途
HK40119609A (en) Aerosolized compositions comprising mitochondria and methods of use thereof
HK40068623B (en) Aerosolized compositions comprising mitochondria and methods of use thereof
HK40068623A (en) Aerosolized compositions comprising mitochondria and methods of use thereof
JPH08109142A (ja) 血小板薬物送達システム
RU2824501C2 (ru) Лечение сердечной недостаточности
US20230129137A1 (en) Use of tt-10-loaded nanoparticles for cardiac repair
Bailey et al. Perfluorocarbon Nanoemulsions Enhance Therapeutic siRNA Delivery in the Treatment of Pulmonary Fibrosis
Bhattarai et al. Karthik Nagapudi, Ajit S. Narang, and Ram I Mahato
Gu et al. Native and Engineered Extracellular Vesicles for the Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
Siddhanta et al. Inhalable Perfluorocarbon Nanocapsules for RNA-based Immunotherapeutic Treatment of Lung Metastases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination